Summary of pooled rates of positive nAb, cellular responses, and AEs
| . | Positive nAb response . | Positive cellular response . | Atleast 1 AE rate . | |||||
|---|---|---|---|---|---|---|---|---|
| Pooled response rate . | 95% CI . | Pooled response rate . | 95% CI . | Pooled response rate . | 95% CI . | I2 (%) . | P . | |
| Overall: Patients with hematologic malignancies | ||||||||
| After second dose | Single arm: 0.60 (single study) | Single arm: 0.40 | 0.00-1.00 | 0.36 | 0.24-0.48 | 97 | <.01 | |
| Malignancy arm of comparator studies: 0.57 (single study) | Malignancy arm of comparator studies: 0.75 (single study) | |||||||
| After first dose | Single arm: 0.63 | 0.00-1.00 | Single arm: 0.86 | 0.00-1.00 | 0.39 | 0.18-0.60 | 97 | <0.01 |
| Malignancy arm of comparator studies: 0.18 | 0.00-0.44 | Malignancy arm of comparator studies: 0.33 (single study) | ||||||
| . | Positive nAb response . | Positive cellular response . | Atleast 1 AE rate . | |||||
|---|---|---|---|---|---|---|---|---|
| Pooled response rate . | 95% CI . | Pooled response rate . | 95% CI . | Pooled response rate . | 95% CI . | I2 (%) . | P . | |
| Overall: Patients with hematologic malignancies | ||||||||
| After second dose | Single arm: 0.60 (single study) | Single arm: 0.40 | 0.00-1.00 | 0.36 | 0.24-0.48 | 97 | <.01 | |
| Malignancy arm of comparator studies: 0.57 (single study) | Malignancy arm of comparator studies: 0.75 (single study) | |||||||
| After first dose | Single arm: 0.63 | 0.00-1.00 | Single arm: 0.86 | 0.00-1.00 | 0.39 | 0.18-0.60 | 97 | <0.01 |
| Malignancy arm of comparator studies: 0.18 | 0.00-0.44 | Malignancy arm of comparator studies: 0.33 (single study) | ||||||